Monoclonal antibody against human uPA

Product No. ADG3689 (replaces no. 3689)

American Diagnostica GmbH
Kaplaneigasse 35 • D-64319 Pfungstadt • Germany
Tel: +49 (0)6157 990899 • Fax: +49 (0 6157 990808

Description

The monoclonal antibody ADG3689 (clone HD-UK1, subclass IgG_1) is a murine monoclonal antibody recognizing human urokinase type plasminogen activator (uPA). The antibody has been purified from cell culture supernatant using Protein G affinity chromatography.

Properties

ADG3689 is directed against a B-chain epitope of human urokinase, near the catalytic site. The antibody reacts with free, and receptor bound, single and two chain (HMW) urokinase, uPA/PAI-1 and, uPA/PAI-2 complexes and the B-chain (33 kDa) fragment.

Presentation

Screw capped vial containing 250 µg of purified antibody in PBS pH 7.1. The IgG concentration is 1 mg/ml. Spin the vial briefly before opening.

Storage and Stability

Store the antibody at 2°-8°C. For long-term storage the antibody should be aliquoted and stored at -20°C or colder. It is recommended to avoid freeze-thaw cycles.

Applications

A. ELISA

The antibody can be used as detedcting antibody in ELISAs. An antibody concentration of 1µg/ml is recommended [1, 2].

B. Immunohistochemistry

The antibody is suitable for staining frozen acetone fixed skin sections [3], and formalin fixed, paraffin embedded sections of cancerous and normal human breast and colon tissue where urokinase is present. Working dilutions range from 1:100 [4] to 1:25 [6].

C. Flow cytometry

The antibody can be used for flow cytometric analysis. An antibody concentration of 10 µg/ml is recommended [7].

D. Western Blot Analysis

The antibody is suitable for Western blot analysis, detecting pro-uPA, HMW-uPA and LMW-uPA after electrophoresis under non-reduced conditions and B-chain fragments under reducing conditions at a working concentration of 1 µg/mL [7, 8].

E. Inhibition

The antibody was shown to inhibit plasminogen activation on the surface of melanoma cell lines. [9].

References

1. Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann. Reinartz J et al., Arch Dermatol Res. 1993;284(8):432-439.
2. Enzyme-linked immunosorbent assays for plasminogen activators. Buessecker F et al., J Immunol Methods. 1993 Jun 18;162(2):193-200.
3. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. Schaefer BM et al., Autoimmunity. 1996;23(3):155-164.
4. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V et al., Cancer. 1996 Mar 15; 77(6):1079-1088.
5. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Sier CF et al., Histopathology. 1991 Sep;19(3):231-237.
6. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Jankun J et al., J Cell Biochem. 1993 Oct;53(2):135-144.
7. Monoclonal antibodies against plasmingen activators and plasmin(ogen). Kramer MD et al, Fibrinolysis. 1991 6 Suppl. 4: 103-111.
8. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). Kobayashi H et al., J Biol Chem. 1991 Mar 15;266(8):5147-5152.
9. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Meissauer A et al., Exp Cell Res. 1992 Apr;199(2):179-190.

ADG3689©ADG23032012